CN117843801A - Novel antibodies and downstream products targeting interleukin family members - Google Patents

Novel antibodies and downstream products targeting interleukin family members Download PDF

Info

Publication number
CN117843801A
CN117843801A CN202311864200.7A CN202311864200A CN117843801A CN 117843801 A CN117843801 A CN 117843801A CN 202311864200 A CN202311864200 A CN 202311864200A CN 117843801 A CN117843801 A CN 117843801A
Authority
CN
China
Prior art keywords
antibody
amino acid
seq
cancer
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202311864200.7A
Other languages
Chinese (zh)
Other versions
CN117843801B (en
Inventor
刘广洋
刘拥军
张晨亮
龙浩淼
徐晓丹
李果
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Beilai Pharmaceutical Co ltd
Original Assignee
Beijing Beilai Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Beilai Pharmaceutical Co ltd filed Critical Beijing Beilai Pharmaceutical Co ltd
Priority to CN202311864200.7A priority Critical patent/CN117843801B/en
Publication of CN117843801A publication Critical patent/CN117843801A/en
Application granted granted Critical
Publication of CN117843801B publication Critical patent/CN117843801B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a novel antibody taking an interleukin family member as a target and a downstream product, belonging to the field of antibodies. The antibody is a tandem antibody, and the tandem antibody comprises the following components: (1) a first single domain antibody: the amino acid sequence comprises: HCDR1, HCDR2, HCDR3 as shown in SEQ ID nos. 1-3; and/or; an amino acid sequence having at least 80% sequence identity to the amino acid sequences shown in SEQ ID NO. 1-3; (2) a second single domain antibody: the amino acid sequence comprises HCDR4, HCDR5 and HCDR6 shown in SEQ ID NO. 4-6; and/or; an amino acid sequence having at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO. 4-6. The antibody has IL-17A specificity, and the characteristics of multiple aspects after tandem are superior to those of single domain antibodies.

Description

Novel antibodies and downstream products targeting interleukin family members
Technical Field
The invention belongs to the field of antibodies, and particularly relates to a novel antibody taking interleukin family members as targets and a downstream product.
Background
IL-17 is a key cytokine associated with host protective mucosal infection, and is also a major causative cytokine and drug target for a variety of autoimmune and inflammatory diseases (Yao, Z.et al Herpesvirus Saimiri encodes a new cytokine, IL-17,which binds to a novel cytokine receptor.Immunity 3,811-821 (1995)). The IL-17 family includes six members: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F, each of which mediates its biological functions through the IL-17 receptor (IL-17 RA to IL-17 RE). Among the most studied IL-17 family members is IL-17A, which promotes its biological activity by binding to IL-17RA and IL-17 RC.
interleukin-17A (IL-17A) is a class of inflammatory cytokines produced by Th17 helper cells, and by binding to the IL-17 receptor on the cell surface, it can promote T cell activation and stimulate the production of various cytokines such AS IL-6, IL-8, GM-CSF and CAM-1 by epithelial cells, endothelial cells, fibroblasts and the like, thereby mediating inflammatory responses, and is closely related to the development of various autoimmune diseases such AS psoriasis, ankylosing Spondylitis (AS) and psoriatic arthritis (PsA). The research shows that the specific blocking of the combination of IL-17A and the receptor thereof can block the signal transmission of inflammatory factors, thereby realizing the purpose of treating psoriasis and other diseases. Currently, antibody drugs blocking IL-17 include monoclonal antibody drugs neutralizing IL-17A (Secukinumab and Ixekizumab) or IL-17RA (Brodalumab), and there are more than 50 antibody drugs or small molecules around the IL-17 target and used for autoimmune disease treatment. Although antibody drugs generally have good therapeutic effects and tolerability in humans compared to chemotherapeutic drugs, there are still many therapeutically relevant side effects in clinical use, such as: nasopharyngitis, headache, nausea and diarrhea or more serious such as infection, cardiotoxicity and severe immune response; in addition, the monoclonal antibody has complex structure and relatively poor stability, so that repeated large-dose injection is required to achieve the optimal effect.
An antibody naturally lacking the light chain is present in alpaca peripheral blood and comprises only one heavy chain variable region (VHH) and two conventional CH2 and CH3 regions, forming a heavy chain antibody. The VHH structure which is cloned and expressed alone has structural stability comparable to that of the original heavy chain antibody and binding activity to the antigen, and is the smallest unit known to bind the antigen of interest. The VHH crystals were 2.5nm long and only 15kDa in molecular weight, also known as Nanobody (Nb). Nanobodies can bind tightly to targets such as antigens like normal antibodies, but do not bind to each other and aggregate into blocks like single chain antibodies. The molecular weight of the nano antibody is only 1/10 of that of the common antibody, the clinical use is safer, the chemical property is more flexible, the stability is good, the solubility is high, the expression is easy, and other molecules are easy to couple, so that the research and development of the IL-17A nano antibody can overcome the defects of the conventional antibody, and has a wide prospect.
The CDR3 length of nanobody is longer than that of general antibody, and the decrease of binding force caused by light chain deletion is compensated to a certain extent, so that it has stronger antigen binding ability (Cai H, yao H, li T, et al improved fluorescent tag and its nanobodies for membrane protein expression, stability assay, and purification.Commun Biol,2020,3 (1): 753.). Nanobodies consist of a complementarity determining region and a framework region. Complementarity determining regions include CDR1, CDR2 and CDR3. B cells in camelid animals differentiate, and the recombinant genes generated by VDJ rearrangement are involved in CDR3 region encoding. Thus, CDR3 regions are associated with the specificity of nanobodies. The length range of 3-28 amino acids of the CDR3 region of the nano antibody ensures the reservoir capacity of the nano antibody reservoir. The framework regions comprise FR1, FR2, FR3 and FR4, and 4 hydrophilic amino acid mutations exist in the FR2, so that the water solubility is improved. The special disulfide bond between CDR1 and CDR3 enhances the stability of the antibody under the conditions of high pressure, high temperature, denaturant and the like, is favorable for the production and the preservation of nano-antibodies, and creates the possibility for a new administration mode.
In the prior art, the anti-IL-7 nano antibody is less researched, and a large development space still exists.
Based on the 9 single domain antibodies (filed in the alternative) screened by anti-IL-17A antibody development, further technical development is carried out, 12 single domain antibody combinations with relatively improved affinity, blocking effect and stability are obtained, and based on the relevant regulations of patent law singleness, 12 different single domain antibody combinations are respectively claimed.
The present invention is a patent application directed to one of the above 12 single domain antibody combination antibodies.
Based on the above, a genetically modified stem cell technology and a subsequent application technology have been developed, and different genetically modified stem cells and different applications are respectively claimed based on relevant regulations of the uniqueness of the patent laws.
For the convenience of understanding the technical solution of the present invention, reference is optionally made to other patent application documents of this project.
Disclosure of Invention
In order to solve the above problems, the present invention provides a novel antibody and downstream products.
The terms "hypervariable region," "complementarity determining region," "HVR," or "CDR," as used herein, refer to regions that are hypervariable in sequence and/or form structurally defined loops ("hypervariable loops") in an antibody variable domain region. Typically, a natural four-chain antibody comprises six HVRs or CDRs: three are present in VH (H1, H2, H3) and three are present in VL (L1, L2, L3). Based on the Chothia definition rules, exemplary CDRs (LCDR 1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR 3) are located at amino acid residues L26-L32 (L1), L50-L52 (L2), L91-L96 (L3), H26-H32 (H1), H52-H56 (H2), and H96-H101 (H3) (Chothia et al, J.mol.biol.196:901-917 (1987)). Based on the Kabat definition rules, exemplary CDRs (LCDR 1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR 3) are located at amino acid residues L24-L34 (L1), L50-L56 (L2), L89-L97 (L3), H31-H35 (H1), H50-H65 (H2), and H95-H102 (H3) (Kabat et al, sequences of Proteins ofImmunological Interest, the fifth edition, public Health Service, national Institutes of Health, bethesda, MD (1991)). Based on IMGT definition rules, exemplary CDRs (LCDR 1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR 3) are located at amino acid residues L27-L32 (L1), L50-L51 (L2), L89-L97 (L3), H26-H33 (H1), H51-H56 (H2), and H93-H102 (H3) (Honjo, T. And Alt, F.W. (1995) Immunoglobulin genes.academic Press pp.3-443). It is well known to those skilled in the art that the CDRs of an antibody can be defined in a variety of ways, such as Kabat definition rules based on sequence variability, chothia definition rules based on structural loop region positions, and reference tools for humanized design of antibodies based on CDR grafting (see J Mol biol.273:927-48, 1997). It will be appreciated by those skilled in the art that unless otherwise specified, the terms "CDR" and "complementarity determining region" of a given antibody or region thereof (e.g., variable region) are to be understood as encompassing complementarity determining regions defined in any of the above known schemes as described by the present invention. Although the scope of the present invention is based on the sequences shown by IMGT definition rules, amino acid sequences corresponding to other CDR definition rules shall also fall within the scope of the present invention.
The scope of the invention is versatile and includes, but is not limited to, the following:
first aspect: an antibody, comprising:
(1) First single domain antibody:
the amino acid sequence comprises: HCDR1, HCDR2, HCDR3 as shown in SEQ ID nos. 1-3; and/or; an amino acid sequence having at least 80% sequence identity to the amino acid sequences shown in SEQ ID NO. 1-3;
(2) Second single domain antibody:
the amino acid sequence comprises HCDR4, HCDR5 and HCDR6 shown in SEQ ID NO. 4-6; and/or; an amino acid sequence having at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO. 4-6.
SEQ ID NO.1：ESLLRLYA；
SEQ ID NO.2：HTTSDTT；
SEQ ID NO.3：HVTSMRDSQNY；
SEQ ID NO.4：TIGLSIYS；
SEQ ID NO.5：ITRRGVT；
SEQ ID NO.6：NVGGEDGY。
Alternatively, the amino acid sequence of the antibody comprises: an amino acid sequence obtained by at least one of addition, deletion, modification and/or substitution on the amino acid sequence shown in SEQ ID NO. 1-6.
Specifically, the amino acid sequence of the antibody comprises: amino acid sequences having a difference of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids compared to the amino acid sequences shown in SEQ ID NO. 1-6.
In some embodiments, the substitution of one or more amino acids may be conservative substitutions of one or more amino acids. Such conservative substitutions are preferably substitutions of one amino acid in the following groups (a) to (e) with another amino acid residue in the same group: (a) small aliphatic, non-polar or weakly polar residues: ala, ser, thr, pro and Gly; (b) Polar, negatively charged residues and (uncharged) amides: asp, asn, glu and Gln; (c) polar, positively charged residues: his, arg and Lys; (d) large aliphatic, nonpolar residues: met, leu, he, val and Cys; and (e) an aromatic residue: phe, tyr and Trp.
In some specific embodiments, conservative substitutions are as follows: ala to Gly or to Ser; arg to Lys; asn to Gln or to His; asp to Glu; cys to Ser; gln to Asn; glu to Asp; gly to Ala or to Pro; his to Asn or to Gln; lie to Leu or to Val; leu to Ile or to Val; lys to Arg, to gin, or to Glu; met to Leu, to Tyr or to Ile; phe to Met, to Leu, or to Tyr; ser to Thr; thr to Ser; trp to Tyr; tyr to Trp; and/or Phe to Val, to Ile or to Leu.
In some expressions, the identical amino acid sequences may also be referred to as functional variants or mutants; in some embodiments, the functional variant is a single domain antibody variant (mutant) having the same or similar affinity or function as the first single domain antibody or the second single domain antibody, e.g., a variant (mutant) that specifically binds IL-17A and blocks IL-17A binding to its receptor.
The first or second single domain antibody may also include a heavy chain framework region for linking the heavy chain variable region, as is generally recognized in the art.
The heavy chain framework region comprises part or all of an antibody heavy chain framework region selected from human, murine, primate, or camelid sources or a variant thereof;
Preferably, the antibody heavy chain framework regions or variants thereof comprise part or all of a source selected from camelids;
more preferably, the heavy chain framework regions of the antibodies or variants thereof are comprised in part or in whole selected from alpaca sources.
Alternatively, the invention may provide an antibody comprising:
a first single domain antibody of the formula (i):
FR1-HCDR1-FR2-HCDR2-FR3-HCDR3-FR4；
(ii) a second single domain antibody, said second single domain antibody having the structure:
FR5-HCDR4-FR6-HCDR5-FR7-HCDR6-FR8；
wherein HCDR1, HCDR2 and HCDR3 are selected from the group consisting of:
amino acid sequences as shown in SEQ ID NO. 1-3; or; amino acid sequence having a 1, 2 or 3 amino acid difference compared to SEQ ID No. 1-3;
HCDR4, HCDR5 and HCDR6 are selected from:
amino acid sequence shown as SEQ ID NO. 4-6; or; amino acid sequence having a 1, 2 or 3 amino acid difference compared to SEQ ID No. 4-6;
FR1, FR2, FR3 and FR4 are selected from: amino acid sequence shown as SEQ ID NO. 7-10; or; an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity compared to SEQ ID No. 7-10;
SEQ ID NO.7：DVQLVESGGGLVQPGGSLRLSCAAS；
SEQ ID NO.8：MGWYRQLPGQEREWVAI；
SEQ ID NO.9：NYRDSVKGRFTLSRDVATNTIYLQMTSLKPEDTAVYYC；
SEQ ID NO.10：WGQGTQVTVSS；
FR5, FR6, FR7 and FR8 are selected from: amino acid sequences as shown in SEQ ID NO. 11-14; or; an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity compared to SEQ ID No. 11-14;
SEQ ID NO.11：QVQLVESGGGLVQPGGSMRLSCAAS；
SEQ ID NO.12：GAWYRQAAGKQRELVAR；
SEQ ID NO.13：NYADSVKGRFTISKDNAKNTVSLEMNSLKPEDTAVYYC；
SEQ ID NO.14：WGQGTQVTVSS。
The amino acid sequence difference is realized by at least one mode of adding, deleting, modifying and/or substituting on the amino acid sequences shown in SEQ ID NO. 1-3.
In some specific embodiments, the HCDR1 has an amino acid sequence shown as SEQ ID No.1, the HCDR2 has an amino acid sequence shown as SEQ ID No.2, the HCDR3 has an amino acid sequence shown as SEQ ID No.3, the HCDR4 has an amino acid sequence shown as SEQ ID No.4, the HCDR5 has an amino acid sequence shown as SEQ ID No.5, and the HCDR6 has an amino acid sequence shown as SEQ ID No. 6.
The amino acid sequences of the first single domain antibody and the second single domain antibody may be directly linked; or; indirectly connected through a linker.
As one preferred in the art, the linker is (GGGGS) n, wherein n is selected from 1, 2, 3, 4, 5 or 6; preferably, the linker is (GGGGS) 3 。
Specifically, the first single domain antibody and the second single domain antibody may be linked in an optional order; or; the first single domain antibody and the second single domain antibody are connected in the order from the N end to the C end; or; the first single domain antibody and the second single domain antibody are linked in order from the C-terminus to the N-terminus.
In some specific effects, the antibody is an anti-IL-17A antibody.
Preferably, the first single domain antibody comprises an amino acid sequence shown as SEQ ID NO. 15;
the second single domain antibody comprises an amino acid sequence shown as SEQ ID NO. 16.
SEQ ID NO.15：
DVQLVESGGGLVQPGGSLRLSCAASESLLRLYAMGWYRQLPGQEREWVAIHTTSDTTNYRDSVKGRFTLSRDVATNTIYLQMTSLKPEDTAVYYCHVTSMRDSQNYWGQGTQVTVSS；
SEQ ID NO.16：
QVQLVESGGGLVQPGGSMRLSCAASTIGLSIYSGAWYRQAAGKQRELVARITRRGVTNYADSVKGRFTISKDNAKNTVSLEMNSLKPEDTAVYYCNVGGEDGYWGQGTQVTVSS。
In practical applications, the tandem nanobody may optionally include a range region and a CH region as required.
Preferably, the sequence of the range region is SEQ ID NO.17, and the sequence of the CH region is SEQ ID NO.18.
SEQ ID NO.17：DKTHTCP；
SEQ ID NO.18：
PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
Second aspect: the present invention provides downstream products of the aforementioned antibodies.
The downstream product may be:
recombinant proteins comprising the aforementioned antibodies; the recombinant protein further comprises a biologically active protein or functional fragment thereof that facilitates expression and/or secretion, or that increases half-life in vivo; the bioactive protein or functional fragment thereof is selected from at least one of an immunoglobulin Fc domain, serum albumin, albumin binding polypeptide, prealbumin, carboxy terminal peptide, elastin-like polypeptide, his tag, GST tag, MBP tag, FLAG tag, and SUMO tag; the immunoglobulin Fc domain is derived from a human antibody, a murine antibody, a primate antibody or a camelid antibody, or a variant thereof; preferably, the immunoglobulin Fc domain is derived from a human IgG antibody, such as an IgG1 Fc, an IgG2 Fc, an IgG3 Fc or an IgG4 Fc, preferably an IgG1 Fc.
In some specific embodiments, the IgG1 Fc has the amino acid sequence shown in SEQ ID NO.19 and the encoding gene is SEQ ID NO.20.
SEQ ID NO.19：
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK；
SEQ ID NO.20
GACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA。
In some embodiments, the recombinant protein may be a monomer, dimer, or multimer.
The downstream product may also be: an antibody formulation, comprising:
a1: any of the antibodies or recombinant proteins previously described; and
a2: a pharmaceutically acceptable carrier.
The pharmaceutically acceptable carrier may be a buffer, sterile water or a surfactant, which may be an ionic or nonionic agent.
The downstream product may also be: a kit comprising any of the antibodies, any recombinant protein or antibody preparation described previously;
optionally, the kit further comprises a container for loading the antibody preparation.
The downstream product may be: a drug conjugate, comprising:
b1: any of the antibodies or recombinant proteins; and
b2: a coupling moiety coupled to B1.
In some embodiments, the coupling moiety comprises a detectable label, drug, toxin, cytokine, radionuclide, or enzyme.
The downstream product may be: an isolated nucleic acid molecule encoding any of the antibodies or recombinant proteins.
Preferably, the nucleic acid has the nucleotide sequence shown as SEQ ID NO. 21:
GATGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGAAAGCCTCCTCAGGTTGTATGCCATGGGCTGGTACCGCCAACTTCCAGGGCAGGAGCGCGAGTGGGTCGCAATACACACTACTAGTGACACCACTAATTATAGAGACTCCGTGAAGGGCCGATTCACGCTCTCCAGAGACGTCGCCACGAACACGATTTATCTCCAAATGACCAGCCTCAAACCTGAAGACACGGCCGTCTATTATTGTCATGTTACTTCCATGAGAGATTCACAAAACTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCGGGAGGCGGAGGATCTGGCGGAGGTGGAAGTGGCGGAGGCGGTTCTCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCTATGAGACTCTCCTGTGCAGCCTCTACGATTGGTCTCAGTATCTATTCCGGGGCCTGGTACCGCCAGGCTGCGGGGAAGCAGCGCGAGTTGGTCGCACGTATTACTAGAAGAGGTGTGACAAACTATGCAGACTCCGTGAAGGGCCGATTTACCATCTCCAAAGACAACGCCAAGAACACGGTGTCTCTGGAAATGAACAGCCTGAAACCTGAGGACACGGCCGTCTACTACTGTAATGTCGGGGGAGAGGATGGCTATTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA。
the downstream product may be: an expression vector comprising said nucleic acid molecule.
Preferably, the types of carriers include, but are not limited to: viral vectors or non-viral vectors.
Further preferably, the viral vector comprises at least one of a lentiviral vector, an adenovirus vector, a baculovirus vector, a retrovirus vector, a poxvirus vector, a sendai virus vector, and a herpes simplex virus vector.
Further preferably, the non-viral vector includes, but is not limited to, a eukaryotic vector or a prokaryotic vector.
The downstream product may be: a pharmaceutical composition comprising any of the antibodies, recombinant proteins, antibody preparations, drug conjugates, nucleic acid molecules, or expression vectors;
optionally, the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.
In some embodiments, the adjuvant is selected from solvents, diluents, disintegrants, precipitation inhibitors, surfactants, glidants, binders, lubricants, dispersants, suspending agents, isotonic agents, thickening agents, emulsifiers, preservatives, stabilizers, hydration agents, emulsifying accelerators, buffers, absorbents, colorants, flavorants, sweeteners, ion exchangers, mold release agents, coating agents, flavoring agents, or antioxidants.
Third aspect: the invention provides the use of the aforementioned antibodies or downstream products.
The use is selected from at least one of the following uses:
c1: preparing a detection reagent or a kit;
c2: preparing a medicament for preventing and/or treating autoimmune diseases;
and C3: preparing medicine for preventing and/or treating cancer.
The autoimmune diseases include, but are not limited to, behcet's disease, systemic lupus erythematosus, chronic discoid lupus erythematosus, multiple sclerosis, systemic scleroderma, progressive systemic sclerosis, scleroderma, polymyositis, dermatomyositis, perinodular arteritis, aortiamatis syndrome, malignant rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, mixed connective tissue disease, kalman's disease, sjogren's syndrome, adult Steve's disease, vasculitis, allergic granulomatous vasculitis, allergic vasculitis, rheumatoid vasculitis, macrovasculitis, ANCA-related vasculitis, cogan's syndrome, RS3PE syndrome, temporal arteritis, polymyositis rheumatica, fibromyalgia, antiphospholipid antibody syndrome, eosinophilic fasciitis, igG 4-related diseases, guillain Barre syndrome, myasthenia gravis chronic atrophic gastritis, autoimmune hepatitis, nonalcoholic steatohepatitis, primary biliary cirrhosis, good-pasture syndrome, acute glomerulonephritis, lupus nephritis, megaloblastic anemia, autoimmune hemolytic anemia, pernicious anemia, autoimmune neutropenia, idiopathic thrombocytopenic purpura, barcup's disease, hashimoto's disease autoimmune hypothyroidism, primary hypothyroidism, addison's disease, idiopathic Addison's disease, type I diabetes, slowly progressive type I diabetes, focal scleroderma, psoriasis, psoriatic arthritis, bullous pemphigoid, herpes gestation, linear IgA bullous dermatoses, acquired bullous epidermolysis, alopecia areata, leukoplakia, vitiligo vulgaris, psoriasis, and chronic adrenal gland hypofunction, neuromyelitis optica, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, sarcoidosis, giant cell arteritis, amyotrophic lateral sclerosis, former field disease, autoimmune optic neuropathy, idiopathic azoospermia, habitual abortion, inflammatory bowel disease, celiac disease, ankylosing spondylitis, severe asthma, chronic urticaria transplantation immunity, familial mediterranean fever, eosinophilic chronic sinusitis, dilated cardiomyopathy, systemic mastocytosis or inclusion body myositis;
Preferably, the autoimmune disease is plaque psoriasis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or lupus nephritis.
Such cancers include, but are not limited to, basal cell carcinoma, cholangiocarcinoma, bladder carcinoma, bone cancer, breast cancer, peritoneal cancer, cervical cancer, cholangiocarcinoma, choriocarcinoma, colorectal cancer, connective tissue carcinoma, digestive system cancer, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer, glioblastoma, liver cancer, renal cancer, laryngeal cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, respiratory system cancer, salivary gland carcinoma, sarcoma, skin cancer, squamous cell carcinoma, testicular cancer, thyroid cancer, uterine cancer, urinary system cancer, B-cell lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, hairy cell leukemia, or chronic myelogenous leukemia.
Fourth aspect: the present invention provides detection methods or therapeutic methods based on the aforementioned antibodies or downstream products.
Specifically provided are: a method for in vitro detection of IL-17A in a sample for non-diagnostic purposes comprising the steps of:
D1: contacting the antibody, recombinant protein, antibody preparation or drug conjugate as described in any of the foregoing with a sample to be tested;
d2: detecting the antigen-antibody complex;
d3: and judging the result.
Specifically provided are: a method of preventing and/or treating an autoimmune disease comprising:
administering to a subject in need thereof a therapeutically effective amount of any of the antibodies, recombinant proteins, antibody preparations or drug conjugates.
Specifically provided are: a method of preventing and/or treating cancer comprising:
administering to a subject in need thereof a therapeutically effective amount of any of the antibodies, recombinant proteins, antibody preparations or drug conjugates.
The mode of administration can be selected and adjusted by those skilled in the art according to the actual circumstances, such as the frequency of administration, the amount of administration, the duration of the word, etc.
The invention has the beneficial effects that:
the serial nano antibody of the invention is obtained by screening the nano antibody obtained by immunizing alpaca, and two kinds of single-domain antibodies used for serial connection are obtained on the basis of the single-domain antibodies. The serial nano antibody has IL-17A specificity, and the characteristics of the serial nano antibody are better than those of single-domain antibodies and positive antibodies, wherein the EC50 of the serial nano antibody combined with target protein in an affinity experiment is 0.7449 mug/mL, which shows that the serial nano antibody has good combining ability; the antibody blocking function experiment can block the Human IL-17A protein from activating 293F-IL-17RA-IL-17Rc-ACT1-NF kappa B-Luc, and the blocking activity is enhanced relative to a single domain antibody and a positive antibody, and the IC50 is 1.155 mug/mL. The serial nano antibody has better stability.
Drawings
FIG. 1 shows the epitope detection results of 1-C11 and 1-F2 single domain antibodies.
FIG. 2 shows SDS-PAGE results of the tandem nanobody C11-1-F2.
FIG. 3 shows the results of antibody affinity assays for Ixekizumab, 1-C11 single domain, 1-F2 single domain, and tandem nanobody C11-1-F2.
FIG. 4 shows the results of Ixekizumab antibody blocking function experiments.
FIG. 5 shows the results of the experiments of the antibody blocking functions of the 1-C11 single domain antibody, the 1-F2 single domain antibody and the serial nano antibody C11-1-F2.
FIG. 6 shows the results of Lxekizumab stability experiments.
FIG. 7 shows the results of stability experiments for single domain antibody (1) (1-C11).
FIG. 8 shows the results of stability experiments for single domain antibody (2) (1-F2).
FIG. 9 shows the results of stability experiments for the tandem nanobody C11-1-F2.
Detailed Description
The present invention will be described in further detail with reference to the following examples, which are not intended to limit the present invention, but are merely illustrative of the present invention. The experimental methods used in the following examples are not specifically described, but the experimental methods in which specific conditions are not specified in the examples are generally carried out under conventional conditions, and the materials, reagents, etc. used in the following examples are commercially available unless otherwise specified.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly used in the art to which this invention belongs. For the purposes of explaining the present specification, the following definitions will apply, and terms used in the singular will also include the plural and vice versa, as appropriate.
The terms "a" and "an" as used herein include plural referents unless the context clearly dictates otherwise. For example, reference to "a cell" includes a plurality of such cells, equivalents thereof known to those skilled in the art, and so forth.
The term "about" as used herein means a range of + -20% of the numerical values thereafter. In some embodiments, the term "about" means a range of ±10% of the numerical value following that. In some embodiments, the term "about" means a range of ±5% of the numerical value following that.
The terms "include" or "comprising" as used herein mean "including but not limited to". The term is intended to be open ended to specify the presence of any stated features, elements, integers, steps, or components, but does not preclude the presence or addition of one or more other features, elements, integers, steps, components, or groups thereof. Thus, the term "comprising" includes the more limiting terms "consisting of … …" and "consisting essentially of … …". In one embodiment, the term "comprising" as used throughout the application, and in particular in the claims, may be replaced by the term "consisting of … …". The amino acid three-letter codes and one-letter codes used herein are as known to those skilled in the art, or as described in J biol. Chem,243, p3558 (1968).
The terms "optional," "any," or "any" used herein mean that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs or does not. For example, "optionally comprising 1 antibody heavy chain variable region" means that an antibody heavy chain variable region of a particular sequence may be, but is not required to be, present.
The term "about" as used herein means a range of + -20% of the numerical values thereafter. In some embodiments, the term "about" means a range of ±10% of the numerical value following that. In some embodiments, the term "about" means a range of ±5% of the numerical value following that.
The term "and/or" as used herein is understood to mean any one of the selectable items or a combination of any two or more of the selectable items.
The term "single domain antibody" (sdAb) or "nanobody" as used herein has its ordinary meaning in the art and refers to an antibody fragment having a molecular weight of only 12-15kDa, which consists of a single monomeric variable antibody domain derived from a heavy chain. Such single domain antibodies (designated VHH) can be found in camelidae mammals and naturally lack the light chain. For a general description of (single) domain antibodies, reference is also made to the above-mentioned prior art and EP 0368684, ward et al (Nature 1989Oct 12;341 (6242): 544-6), holter et al Trends Biotechnol,2003,21 (11): 484-490; and WO 06/030220, WO 06/003388. The amino acid sequence and structure of a single domain antibody can be considered to consist of four framework regions or "FR", which are referred to in the art as "framework region 1" or "FR1", respectively; "frame region 2" or "FR2"; is "frame region 3" or "FR3"; "frame region 4" or "FR4"; the framework regions are separated by three complementarity determining regions or "CDRs", referred to in the art as "complementarity determining region 1" or "CDR1", respectively; "complementarity determining region 2" or "CDR2", and "complementarity determining region 3" or "CDR3". Thus, a single domain antibody can be defined as an amino acid sequence having the general structure: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, wherein FR1-FR4 refers to framework regions 1-4, respectively, and wherein CDR1-CDR3 refers to complementarity determining regions 1-3. In the context of the present disclosure, the amino acid residues of a single domain antibody are numbered according to the general numbering of the VH domains given by amino acid numbering International ImMunoGeneTicsinformation system (http:// imgt. Cmes. Fr /).
The term "amino acid" as used herein refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as modified amino acids such as hydroxyproline, gamma-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., a carbon bound to hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. These analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to compounds that differ in structure from the general chemical structure of an amino acid, but function in a manner similar to naturally occurring amino acids.
The terms "activity", "functional activity" or "biological activity", or the terms "biological property" or "biological feature" as used herein are used interchangeably and include, but are not limited to, epitope/antigen affinity and specificity, the ability to neutralize or antagonize IL-17A activity in vivo or in vitro, IC50, in vivo stability of antibodies, and immunogenic properties of antibodies. Other identifiable biological properties or characteristics of antibodies known in the art include, for example, cross-reactivity (i.e., cross-reactivity with non-human homologs of the targeting peptide in general, or with other proteins or tissues), and the ability to maintain high levels of expression of the protein in mammalian cells. The aforementioned properties or characteristics are observed, assayed or assessed using techniques well known in the art, including but not limited to ELISA, FACS or BIACORE plasma resonance analysis, unrestricted in vitro or in vivo neutralization assays, receptor binding, cytokine or growth factor production and/or secretion, signal transduction, and immunohistochemistry of tissue sections of different origin (including human, primate or any other source).
The term "Fc" or "Fc region", "Fc domain" or "Fc fragment" as used herein refers to a polypeptide consisting of the CH2 and CH3 domains of IgA, igD and IgG, or the CH2, CH3 and CH4 domains of IgE and IgM through a hinge region. Although the breakdown of the Fc fragment is variable, the heavy chain Fc fragment of human IgG generally refers to the polypeptide from A231 to its carboxy terminus.
The term "epitope" as used herein refers to a protein determinant capable of specific binding to an antibody. Epitopes are typically composed of surface-clustered molecules, such as amino acids or sugar side chains, and typically have specific three-dimensional structural features, as well as specific charge features. Conformational and non-conformational epitopes differ in that binding to the former but not the latter is lost in the presence of denaturing solvents. Epitopes can include amino acid residues that are directly involved in binding and other amino acid residues that are not directly involved in binding, such as amino acid residues that are effectively blocked or covered by a specific antigen binding peptide (in other words, amino acid residues are within the footprint of a specific antigen binding peptide).
The term "affinity" or "binding affinity" as used herein refers to an inherent binding affinity that reflects interactions between members of a binding pair. Affinity can be measured by common methods known in the art. One specific method for measuring affinity is the ForteBio kinetic binding assay herein.
The term "antibody drug conjugate" as used herein refers to a substance obtained by linking a biologically active compound fragment to an antibody or antigen binding fragment portion thereof. The biologically active compound fragment and the targeting moiety may be linked by a linker. The linker is capable of cleaving in a specific environment (e.g., an intracellular low pH environment) or under a specific action (e.g., action of a lysosomal protease) to thereby separate the biologically active compound fragment from the targeting moiety or antibody or antigen binding fragment thereof. The linker comprises a cleavable or non-cleavable unit, such as a peptide or disulfide bond. The biologically active compound fragment is directly linked to the targeting moiety or antibody or antigen binding fragment thereof by a covalent bond that is capable of cleavage under a specific environment or action, thereby separating the biologically active compound fragment from the antibody or antigen binding fragment portion thereof.
The term "nucleic acid" or "polynucleotide" as used herein refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single or double stranded form. Unless specifically limited, the term includes nucleic acids containing known analogues of natural nucleotides that have similar binding properties to the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides (see, U.S. Pat. No.8278036 to Kariko et al, which discloses mRNA molecules with uridine replaced by pseudouridine, methods of synthesizing the mRNA molecules, and methods for delivering therapeutic proteins in vivo). Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed bases and/or deoxyinosine residues (Batzer, nucleic Acid Res.19:5081 (1991); ohtsuka, J.biol.chem.260:2605-2608 (1985); rossolini, mol.cell.probes 8:91-98 (1994)).
The term "isolated nucleic acid" as used herein is a nucleic acid that has been identified and isolated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in a cell that typically contains the nucleic acid molecule, but the nucleic acid molecule is present at a chromosomal location that is extrachromosomal or different from its natural chromosomal location.
The term "construct" as used herein refers to any recombinant polynucleotide molecule (such as a plasmid, cosmid, virus, autonomously replicating polynucleotide molecule, phage, or linear or circular single-or double-stranded DNA or RNA polynucleotide molecule), derived from any source, capable of integrating with the genome or autonomously replicating, constituting a polynucleotide molecule in which one or more polynucleotide molecules have been functionally linked (i.e., operably linked). Recombinant constructs will typically comprise a polynucleotide of the invention operably linked to transcriptional initiation regulatory sequences that direct the transcription of the polynucleotide in a host cell. Both heterologous and non-heterologous (i.e., endogenous) promoters may be used to direct expression of the nucleic acids of the invention.
The term "vector" as used herein refers to any recombinant polynucleotide construct that can be used for transformation purposes (i.e., the introduction of heterologous DNA into a host cell). One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, in which additional DNA segments can be ligated into the viral genome. Some vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Upon introduction into a host cell, other vectors (e.g., non-episomal mammalian vectors) integrate into the genome of the host cell and thereby replicate together with the host genome. In addition, certain vectors are capable of directing the expression of genes that are operably linked. Such vectors are referred to herein as "expression vectors".
The term "expression vector" as used herein refers to a nucleic acid molecule capable of replicating and expressing a gene of interest when transformed, transfected or transduced into a host cell. The expression vector contains one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to provide amplification in the host if desired.
The terms "cell", "cell line" are used interchangeably herein and all such designations include progeny thereof. The term "host cell" refers to a cell that can be used to introduce a vector, and includes, but is not limited to, a prokaryotic cell such as E.coli, a fungal cell such as a yeast cell, or an animal cell such as a fibroblast, CHO cell, COS cell, NSO cell, heLa cell, BHK cell, HEK 293 cell, or human cell.
The term "pharmaceutical composition" as used herein generally refers to a formulation that exists in a form that allows for the biological activity of the active ingredient to be effective and that does not contain additional ingredients that have unacceptable toxicity to the subject to which the composition is to be administered. The composition is sterile.
The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. As used herein, the term "pharmaceutically acceptable carrier, excipient and/or diluent" refers to a carrier that is pharmacologically and/or physiologically compatible with the subject and active ingredient, as is well known in the art (see, e.g., remington's Pharmaceutical sciences. Mediated by Gennaro AR,19th ed.Pennsylvania:Mack Publishing Company,1995). A pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, medium, encapsulating material, manufacturing aid or solvent encapsulating material, which is involved in maintaining the stability, solubility or activity of an antibody or antigen binding fragment thereof of the present disclosure, and includes, but is not limited to: pH modifiers, surfactants, adjuvants, ionic strength enhancers, diluents, agents to maintain osmotic pressure, agents to delay absorption, preservatives. For example, pH adjusters include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. Agents that maintain osmotic pressure include, but are not limited to, sugar, naCl, and the like. Agents that delay absorption include, but are not limited to, monostearates and gelatin. Diluents include, but are not limited to, water, aqueous buffers (e.g., buffered saline), alcohols and polyols (e.g., glycerol), and the like. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, and the like. Stabilizers have the meaning commonly understood by those skilled in the art and are capable of stabilizing the desired activity of the active ingredient in a medicament, including but not limited to sodium glutamate, gelatin, SPGA, saccharides (e.g., sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (e.g., glutamic acid, glycine), proteins (e.g., dried whey, albumin or casein) or degradation products thereof (e.g., lactalbumin hydrolysate), and the like.
The term "subject" as used herein includes any human or non-human animal. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, and the like.
The terms "therapeutically effective amount," "therapeutically effective dose," and "effective amount" as used herein refer to an amount of an anti-IL-17A antibody or antigen-binding fragment thereof of the invention that is effective to prevent or ameliorate a symptom of one or more diseases or conditions, or the development of the disease or condition, when administered to a cell, tissue, or subject, alone or in combination with other therapeutic agents. A therapeutically effective dose also refers to an amount of an antibody or antigen binding fragment thereof sufficient to result in an improvement in symptoms, e.g., to treat, cure, prevent, or ameliorate a related medical condition, or to increase the rate of treatment, cure, prevention, or amelioration of such a condition. When an active ingredient is administered to an individual, a therapeutically effective dose refers to that ingredient alone. When administered in combination, a therapeutically effective dose refers to the combined amount of the active ingredients that results in a therapeutic effect, whether administered in combination, sequentially or simultaneously. An effective amount of the therapeutic agent will result in an increase in the diagnostic criteria or parameter of at least 10%; typically at least 20%; preferably at least about 30%; more preferably at least 40%, most preferably at least 50%.
The term "EC50" as used herein refers to the half maximal effect concentration (concentration for 50%of maximal effect), i.e., the concentration that causes 50% of the maximal effect (in this context: ability to bind IL-17A).
The term "IC50" as used herein refers to a half inhibitory concentration (half maximal inhibitory concentration), i.e., a concentration that causes a 50% maximum inhibitory effect (in this context: the ability to inhibit IL-17A and its receptor IL-17RA binding).
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. Numerous specific details are set forth in the following description in order to provide a better understanding of the invention. The specific embodiments described herein are for purposes of illustration only and are not to be construed as limiting the invention in any way. In addition, in the following description, descriptions of well-known structures and techniques are omitted so as not to unnecessarily obscure the present invention. Such structures and techniques are also described in a number of publications.
The reagents, materials and equipment that may be involved in the present invention are shown in Table 1.
TABLE 1 Main reagents, materials and apparatus according to the invention
/>
The primers used for screening and cloning VHH fragments and constructing nanobodies are designed by referring to the following documents:
Maass DR,Sepulveda J,Pernthaner A,Shoemaker CB.Alpaca(Lama pacos)as a convenient source of recombinant camelid heavy chain antibodies(VHHs).JImmunol Methods.2007；324(1-2):13-25.
Lin,J,Gu,Y,Xu,Y et al.Characterization and applications of nanobodies against Pseudomonas aeruginosa exotoxin a selected from single alpaca B cells.Biotechnol Biotechnol Equip 2020；34:1028-37.
Studies on design of singledomain antibodies by AlpacaVHH phage library and high throughput sequencing toconstruct Fab antibody purification system(http://hdl.handle.net/10232/00030916).
basic Experimental example IL-17 nanobody screening
As embodied in the invention patent of the same date of application, the invention obtains a plurality of schemes by screening antibodies by antigen immunized animals, wherein the screening comprises the following steps:
(1) Preparation of recombinant antigens
Adding a 6 XHis tag at the C end of the IL-17 antigen, performing gene synthesis after optimizing according to a prokaryotic codon, and subcloning into a pET28a vector; after being verified by Sanger sequencing, the plasmid is extracted; transforming the recombinant plasmid into BL21 competent, inducing overnight with 0.5mM IPTG, and collecting bacterial liquid for cleavage; purifying the recombinant protein using a nickel column; purity of the target protein was checked by SDS-PAGE.
BL21 is adopted to express IL-17A recombinant protein and nickel column is used for purification, SDS-PAGE is used for detecting the purity of target protein, and the purity of IL-17A antigen protein is more than 90% after being purified.
(2) Preparation of positive control antibody Ixekizumab
Ixekizumab heavy chain variable region: SEQ ID NO.22; light chain variable region SEQ ID NO.23.
SEQ ID NO.22：
QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS；
SEQ ID NO.23：
DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK。
SDS-PAGE detects the purity of the positive control antibody protein >95%.
(3) The positive control antibody is used for detecting the binding capacity of the recombinant antigen, and the result shows that the positive antibody and the IL-17A antigen protein are well combined and can be used for subsequent immunization.
(4) Human IL-17A recombinant protein activity detection
The detection was performed using an IL-17A protein activated NIH-3T3 cell assay. NIH-3T3 cells were treated with the prepared recombinant IL-17A (TEST) and purchased IL-17A (Acro), respectively, and supernatants were collected after 72 hours to examine the secretion of mIL-6, and according to the examination results, IL-17A antigen protein had an activity of activating the expression of mIL-6 by NIH-3T3 cells, and IL-17A (TEST, hereinafter referred to as IL-17A recombinant protein) activity positively correlated with the concentration thereof, and was used for immunization.
(5) Construction and verification of IL-17A reporter gene cell strain
Based on the amino acid sequence information of IL-17RA (UniProtKB: Q96F 46) and IL-17RC (UniProtKB: Q8NAC 3), a lentiviral expression vector is constructed, lentivirus is packaged, 293 cells are co-infected, recombinant 293 cells which simultaneously overexpress the two receptors are screened, NFKB-Luciferase (SEQ ID NO. 24) and ACT1 (SEQ ID NO. 25) genes are further stably transformed, and an IL-17A reporter cell strain 293F-IL-17RA-IL-17Rc-ACT1-nfκB-Luc is constructed.
SEQ ID NO.24：
ATGGAAGATGCCAAAAACATTAAGAAGGGCCCAGCGCCATTCTACCCACTCGAAGACGGGACCGCCGGCGAGCAGCTGCACAAAGCCATGAAGCGCTACGCCCTGGTGCCCGGCACCATCGCCTTTACCGACGCACATATCGAGGTGGACATTACCTACGCCGAGTACTTCGAGATGAGCGTTCGGCTGGCAGAAGCTATGAAGCGCTATGGGCTGAATACAAACCATCGGATCGTGGTGTGCAGCGAGAATAGCTTGCAGTTCTTCATGCCCGTGTTGGGTGCCCTGTTCATCGGTGTGGCTGTGGCCCCAGCTAACGACATCTACAACGAGCGCGAGCTGCTGAACAGCATGGGCATCAGCCAGCCCACCGTCGTATTCGTGAGCAAGAAAGGGCTGCAAAAGATCCTCAACGTGCAAAAGAAGCTACCGATCATACAAAAGATCATCATCATGGATAGCAAGACCGACTACCAGGGCTTCCAAAGCATGTACACCTTCGTGACTTCCCATTTGCCACCCGGCTTCAACGAGTACGACTTCGTGCCCGAGAGCTTCGACCGGGACAAAACCATCGCCCTGATCATGAACAGTAGTGGCAGTACCGGATTGCCCAAGGGCGTAGCCCTACCGCACCGCACCGCTTGTGTCCGATTCAGTCATGCCCGCGACCCCATCTTCGGCAACCAGATCATCCCCGACACCGCTATCCTCAGCGTGGTGCCATTTCACCACGGCTTCGGCATGTTCACCACGCTGGGCTACTTGATCTGCGGCTTTCGGGTCGTGCTCATGTACCGCTTCGAGGAGGAGCTATTCTTGCGCAGCTTGCAAGACTATAAGATTCAATCTGCCCTGCTGGTGCCCACACTATTTAGCTTCTTCGCTAAGAGCACTCTCATCGACAAGTACGACCTAAGCAACTTGCACGAGATCGCCAGCGGCGGGGCGCCGCTCAGCAAGGAGGTAGGTGAGGCCGTGGCCAAACGCTTCCACCTACCAGGCATCCGCCAGGGCTACGGCCTGACAGAAACAACCAGCGCCATTCTGATCACCCCCGAAGGGGACGACAAGCCTGGCGCAGTAGGCAAGGTGGTGCCCTTCTTCGAGGCTAAGGTGGTGGACTTGGACACCGGTAAGACACTGGGTGTGAACCAGCGCGGCGAGCTGTGCGTCCGTGGCCCCATGATCATGAGCGGCTACGTTAACAACCCCGAGGCTACAAACGCTCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTGGACCGGCTGAAGAGCCTGATCAAATACAAGGGCTACCAGGTAGCCCCAGCCGAACTGGAGAGCATCCTGCTGCAACACCCCAACATCTTCGACGCCGGGGTCGCCGGCCTGCCCGACGACGATGCCGGCGAGCTGCCCGCCGCAGTCGTCGTGCTGGAACACGGTAAAACCATGACCGAGAAGGAGATCGTGGACTATGTGGCCAGCCAGGTTACAACCGCCAAGAAGCTGCGCGGTGGTGTTGTGTTCGTGGACGAGGTGCCTAAAGGACTGACCGGCAAGTTGGACGCCCGCAAGATCCGCGAGATTCTCATTAAGGCCAAGAAGGGCGGCAAGATCGCCGTG；
SEQ ID NO.25：
ATGCCACCTCAGTTGCAGGAAACTCGGATGAATAGAAGCATCCCCGTGGAAGTGGACGAGAGCGAGCCGTACCCTAGTCAGCTGCTGAAGCCGATCCCTGAGTACTCCCCGGAAGAGGAATCCGAACCACCAGCCCCCAACATTCGCAATATGGCCCCCAATAGCTTGTCCGCACCAACAATGCTGCACAACTCTTCTGGCGACTTCTCTCAGGCCCACTCCACCCTGAAACTGGCGAATCACCAGCGGCCTGTATCCCGGCAGGTGACCTGTCTGAGAACTCAGGTGCTTGAAGACTCCGAGGACTCTTTCTGTAGGCGGCATCCAGGTTTGGGCAAGGCGTTTCCGTCCGGCTGTTCCGCGGTTTCAGAGCCCGCTTCCGAAAGTGTCGTGGGCGCCCTGCCAGCCGAGCACCAGTTCTCCTTCATGGAAAAGCGGAACCAGTGGCTGGTCAGTCAGCTGAGCGCCGCGTCACCTGATACAGGTCACGATTCCGACAAGTCTGACCAGTCTCTGCCCAATGCGTCAGCCGATAGTCTCGGGGGCTCCCAGGAGATGGTGCAGAGACCACAGCCGCACAGAAACCGGGCCGGGCTTGATCTGCCCACCATTGATACAGGCTACGATTCCCAGCCCCAGGACGTCCTTGGCATTCGCCAGCTGGAAAGGCCTCTGCCCTTGACCTCCGTGTGTTACCCCCAGGACCTGCCCCGCCCTTTGAGAAGCCGGGAGTTTCCCCAGTTTGAGCCCCAACGATACCCTGCCTGTGCTCAGATGCTGCCTCCGAACCTGAGCCCACACGCTCCCTGGAACTACCACTATCACTGTCCCGGCAGCCCCGATCACCAGGTGCCTTATGGACACGACTACCCGCGGGCTGCATACCAGCAGGTCATACAGCCTGCCTTGCCGGGTCAGCCGCTGCCCGGAGCTTCTGTGCGCGGCCTGCACCCCGTTCAGAAAGTGATCCTGAACTATCCAAGCCCATGGGACCATGAAGAGAGACCAGCCCAAAGAGATTGCTCTTTTCCTGGGTTGCCTAGACACCAAGACCAGCCTCACCACCAGCCTCCCAATCGGGCAGGCGCCCCAGGCGAAAGTCTCGAGTGCCCCGCCGAACTCAGACCACAGGTCCCTCAGCCCCCTTCCCCCGCGGCAGTACCCAGACCCCCCTCTAACCCACCCGCCCGGGGAACGCTCAAGACTTCAAATCTCCCAGAAGAGCTGCGCAAAGTGTTCATAACCTACAGCATGGACACCGCTATGGAGGTGGTTAAGTTCGTCAACTTCCTGCTGGTCAATGGGTTCCAGACTGCAATCGACATTTTTGAGGATAGAATTCGGGGAATCGACATCATCAAGTGGATGGAGAGATACCTGCGGGATAAGACAGTGATGATTATCGTGGCCATTAGTCCCAAGTACAAGCAAGATGTGGAGGGCGCAGAATCACAGTTGGACGAAGACGAGCACGGACTCCATACAAAATATATCCACAGGATGATGCAGATCGAGTTCATTAAACAAGGCTCCATGAATTTCCGCTTCATACCGGTCCTGTTTCCAAACGCAAAAAAAGAGCATGTACCCACTTGGCTCCAGAATACCCATGTCTACTCCTGGCCCAAGAACAAGAAGAATATCCTGCTGCGCTTGCTCAGAGAAGAAGAGTATGTCGCCCCTCCAAGGGGGCCCCTCCCCACACTCCAAGTAGTGCCACTT。
And adding a recombinant antigen for activation, adding a positive control antibody Ixekizumab for detection of a blocking experiment, calculating an EC50 value of the blocking experiment, and establishing a candidate antibody in vitro pharmacodynamics evaluation cell strain targeting IL-17A. FACS results found: the constructed IL-17A receptor over-expression cell strain can be combined with IL-17A, and the positive rate is more than 90%.
The IL-17A recombinant protein is adopted to activate 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc, and the IL-17A recombinant protein can effectively activate luciferase expression in 293F-IL17RA-IL17 Rc-NFkB-Luc reporter gene cell strain.
The positive control antibody Ixekizumab and the IL-17A recombinant protein are added into 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc cells together, and the positive control antibody Ixekizumab can inhibit the combination of IL17A protein and a membrane receptor thereof and inhibit the signal of intracellular NFkB and present a dose effect.
(6) Alpaca immunity
Immunization is carried out on Alpaca (Alpaca) by using the prepared recombinant antigen protein, the immunization interval is 21 days, partial peripheral blood is collected after 10 days of the last immunization, and ELISA detection is carried out on the immune effect of the separated serum.
(7) Detection of immune titers
The immunological titers of alpaca reached the requirements after 6 rounds of immunization (see tables 2-3 below).
TABLE 2 results of immunotiter assays
TABLE 3 results of immunotiter assays
/>
(8) PBMC isolation and VHH antibody fragment cloning
PBMC were isolated, RNA was extracted and subjected to two rounds of PCR after reverse transcription, the products were recovered, and the concentration was determined.
(9) Construction and panning of Single-Domain antibody Yeast display libraries
The linear vector and the PCR product together electrically transformed the yeast competent strain.
(10) Single domain antibody yeast display pool panning.
(11) After panning, yeast monoclonal was subjected to flow detection.
(12) Amplification, transient transfection and detection of the overlay PCR product, recovery of the product, transfection.
(13) ELISA selects positive clones, VHH antibody sequences are obtained, gene synthesis is carried out, and Protein A columns are purified after genetic engineering expression.
Enriching positive clones; and selecting the enriched monoclonal, performing Phage ELISA identification, and performing sequencing analysis on the clone to obtain the nucleic acid and amino acid sequence information of the candidate single domain antibody. 20 monoclonals are randomly selected for sequencing analysis, the sequence difference is large, and the library diversity is good. The potential post-translational modification sites were analyzed by the In silico method against the amino acid sequence information of the CDR regions of the candidate single domain antibodies.
According to the result of the monoclonal flow detection of the yeast, positive clones combined with IL-17A-His are selected to extract genome DNA, and the antibody sequence is obtained by PCR. According to the sequencing result of the PCR product, selecting differential clone for overlap PCR amplification, adding signal peptide at the N end of VHH, adding IgG1-Fc at the C end, and transiently transfecting HEK293 cells with the PCR product; ELISA detection was performed on the expressed antibody supernatants: 100. Mu.L of transfection supernatant was incubated in 96-well plates pre-coated with IL-17A recombinant antibody and ELISA detection was performed using HRP-Protein A as secondary antibody, the results are shown in Table 4: all clones except 1-B11 which did not bind IL-17A-His antigen, the remaining 14 clones were all bound, and these 14 differential clones were arranged to construct eukaryotic expression vectors, see Table 4.
TABLE 4 ELISA Binding assay results for candidate clone transfected supernatants
/>
The constructed single domain antibody expression vector is transiently transfected into 293F cells, recombinant antibodies are affinity purified by Protein A, and SDS-PAGE experiments are carried out to detect the purity of candidate antibodies. The results show that the molecular weight and purity of the candidate antibodies are all in accordance with the expectations, and the next experiment can be carried out.
(14) ELISA detection of binding of recombinant antibodies to target proteins
(15) FACS detection of IL17A binding to reporter cell lines
(16) Single domain antibody blocking function assay
Antibodies were diluted in a gradient, IL-17A protein, 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc cells were added, 20. Mu.L Bright-GloTM assay reagent was added, and luciferase activity values in wells were detected using a Tecan M1000pro microplate reader.
(17) Single domain antibody epitope detection (NTA)
The ForteBio OCTET R2 system was subjected to kinetic characterization analysis.
(18) Single domain antibody epitope detection (HIS 1K)
Kinetic characterization analysis was performed using the ForteBio OCTET R2 system.
The invention further extends to the basis of the basic screening method described above. In the detection of the blocking activity of the antibody, the blocking effect of a part of single domain antibodies is weaker than that of a positive antibody Ixekizumab although the single domain antibodies can block the Human IL-17A protein from activating a downstream target protein. Thus, two of the anti-IL-17A single domain antibodies are serially combined to form a bivalent antibody to enhance its blocking effect. Specifically, the present invention protects tandem nanobodies constructed by 1-C11 and 1-F2 shown in Table 4. The two have different antibody epitopes, and the detection results of the 1-C11 and 1-F2 single domain antibody epitopes are shown in figure 1.
Example 1 preparation and purification of IL-17A specific tandem nanobodies
The sequence of the 1-C11 variable region is SEQ ID NO.15, and the HCDR region is SEQ ID NO.1-3 in sequence;
the sequence of the 1-F2 variable region is SEQ ID NO.16, and the HCDR region is SEQ ID NO.4-6 in sequence.
In this example, the tandem nanobody may further include a linker (GGGGS) 3 Finger region (S)EQ ID No. 17) and CH region (SEQ ID No. 18).
The tandem nanobody in this example is abbreviated as C11-1-F2, and its amino acid sequence is SEQ ID NO.15- (GGGGS) 3 -SEQ ID NO.16-SEQ ID NO.17-SEQ ID NO.18, the gene sequence of which is SEQ ID NO.21.
The tandem nanobody of the present embodiment can be prepared by referring to the antibody preparation method in the prior art, specifically as follows:
(1) The gene SEQ ID No.21 is synthesized and subcloned into an expression vector pcDNA3.4-hIgG1-Fc in tandem with a human IgG1 Fc segment gene sequence (SEQ ID No. 20). After the vector was verified by sequencing, the endotoxin-free plasmid was prepared using the Qiagen plasmid large-sample kit (CAT#: DP 117) for use.
(2) And taking out the LVTransm transfection reagent and the single-chain antibody expression vector from the refrigerator, thawing at room temperature, and blowing up and down by a pipetting gun to completely mix uniformly. The PBS buffer was removed and warmed to room temperature. Taking 2mL of PBS to one hole of a 6-hole plate, respectively adding 130 mug antibody expression vector, blowing up and down by a pipetting gun, fully and uniformly mixing, adding 400 mug LVTransm, immediately blowing up and down by a pipetting device, uniformly mixing, and standing for 10 minutes at room temperature to obtain the DNA/LVTransm compound.
(3) The DNA/LVTransm complex was added to 30mL of 293F cells, and the mixture was thoroughly mixed with gentle shaking. The cells were exposed to 5% CO at 37 ℃ 2 After culturing for 6-8 hours at 130rpm in the incubator, 50mL of fresh 293 cell culture medium was added and the cells were returned to the incubator for continued culturing.
After continuous culture for 7 days, the culture supernatant was collected by centrifugation, filtered with a 0.45 μm filter membrane, and the filtrate was transferred to a sterile centrifuge tube, and the antibody was purified using Protein A to obtain a purified antibody.
The procedure for purifying antibodies by Protein A is as follows:
1) Samples containing the target antibodies were added to the EP tube and mixed by gently inverting the tube.
2) EP tubes were mixed at room temperature or incubated on a rotator, (1-4 hours or overnight) and 100mM PMSF was added to prevent protein degradation.
3) The magnetic beads were collected using a magnetic separation rack and the supernatant was discarded. The supernatant was retained for analysis, if necessary.
4) To the EP tube, 1mL of binding/washing buffer was added and thoroughly mixed, the beads were collected using a magnetic rack and the supernatant was discarded, and the washing step was repeated three times.
5) To the EP tube, 500. Mu.L of elution buffer was added, and resuspended rapidly with pipetting or vortexing, and then incubated at room temperature (about 25 ℃) for 5 minutes either in a tumble mixer or by manually gently tumbling the EP tube.
6) Magnetic beads were collected using a magnetic separation rack and the supernatant containing the eluted antibodies was transferred to a clean EP tube.
7) Steps 1) and 2) were repeated twice.
8) To each 500. Mu.L of eluate, 1/10 of a neutralization buffer was added to neutralize the pH in order to maintain the biological activity of the antibody and avoid inactivation of the antibody. Buffer exchange can be performed by dialysis or desalting, if desired.
9) Binding/washing buffer: 1 XPBS, pH 7.0.
Elution buffer: (1) 0.1M glycine, pH 2-3; (2) 0.1M NaAc-HAc, pH 3.6.
Neutralization buffer: 1M Tris, pH 8.5.
Magnetic bead regeneration buffer: 0.1M NaOH.
SDS-PAGE results of the tandem nanobody C11-1-F2 are shown in FIG. 2.
SDS-PAGE detects the purity of the target antibody protein, and the result shows that the protein purity is >95%.
Example 2 IL-17A specific tandem nanobody affinity assay
Using Ixekizumab as a positive control, synthesizing Ixekizumab heavy chain variable region (SEQ ID NO. 22) and light chain variable region (SEQ ID NO. 23) by genes, subcloning the heavy chain variable region into pcDNA3.4-hIgG4 vector (hIgG 4 amino acid sequence is SEQ ID NO. 26), and subcloning the light chain variable region into pcDNA3.4-hIgKc vector (hIgKc amino acid sequence is SEQ ID NO. 27); after verification by Sanger sequencing, the plasmid megapump kit is used for preparing the endotoxin-removing plasmid for standby. Other procedures reference example 1 was made to control antibodies with a purity >95%.
SEQ ID NO.26：
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK；
SEQ ID NO.27：
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC。
Simultaneously with single domain antibody (1): SEQ ID No.15-SEQ ID No.17-SEQ ID No.18 and single domain antibody (2): SEQ ID NO.16-SEQ ID NO.17-SEQ ID NO.18 as a control, prepared by referring to the tandem nanobody preparation method.
ELISA detects binding of recombinant antibodies to target proteins:
coating an ELISA plate with the purified antibody to be detected (2 ug/mL), adding Biotin-IL-17A-His, diluting 7 points with a 5-fold gradient, performing ELISA detection with HRP-strepitavdin, and drawing a curve of OD450 values measured by each concentration to read EC50 values.
The results (as in fig. 3) show that:
the EC50 value of the control antibody Ixekizumab is 10.06 μg/mL;
the EC50 of the single domain antibody (1) (1-C11) was 29.99. Mu.g/mL;
the EC50 of the single domain antibody (2) (1-F2) was 4.039 μg/mL;
the EC50 of the tandem nanobody C11-1-F2 was 0.7449. Mu.g/mL.
The binding capacity of the tandem nanobody C11-1-F2 is obviously superior to that of a positive control antibody.
Example 3 antibody blocking function assay
Blocking activity assays were performed using the 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc reporter cell line. This example detects tandem nanobodies, control antibodies and single domain antibodies as described in example 2.
Ixekizumab results are shown in FIG. 4, and can block Human IL-17A protein from activating 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc, and the IC50 value is 1.356 mug/mL.
The results of the single domain antibody (1), the single domain antibody (2) and the tandem nanobody are shown in FIG. 5, and can block the Human IL-17A protein from activating 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc.
The IC50 value of the single domain antibody (1) is 18.80 mug/mL; the IC50 value of the single domain antibody (2) is 14.22 mug/mL; the IC50 of the tandem nanobody C11-1-F2 was 1.155. Mu.g/mL. IC50 results data indicate that tandem nanobodies do enhance blocking activity relative to single domain antibodies and are superior to positive control antibodies.
Example 4 stability test procedure and results analysis:
the experimental process comprises the following steps: by detecting fluorescence change through a micro-differential scanning fluorescence (nanoDSF) technique, thermal denaturation and chemical denaturation of proteins can be detected under natural conditions, and the temperature (Tm) at which 50% of the proteins are in an unfolded state and the temperature (Tagg) at which aggregation begins to occur can be accurately determined; the higher the thermal denaturation Tm value and Tagg, the more stable the antibody protein.
Taking 100 mu L of antibody to be detected, centrifuging at 4 ℃ for 10min at 12000 Xg, sucking samples by using capillaries, preparing two capillaries for each sample, taking the capillaries as parallel control, sequentially placing the capillaries into corresponding clamping grooves, ensuring that the capillaries are full of the samples, and carrying out detection analysis. The temperature rising range is 20-95 ℃, the temperature rising rate is 1 ℃/min, and the detection time is 75min.
Tm is defined as the melting temperature, tonset is defined as the temperature at which unfolding begins, tagg is defined as the aggregation temperature.
The antibodies to be detected in this example are the tandem nanobody, the control antibody, and the single domain antibody described in example 2.
Lxekizumab results are shown in FIG. 6; the Tm1 value thereof is 56.10+/-0.02 ℃; the Tm2 value is 79.84+ -0.13 ℃; the TONSet value is 47.50 +/-0.08 ℃; the Tagg value is 61.86+/-0.23 ℃;
the results for single domain antibody (1) are shown in FIG. 7; the Tm1 value thereof is 64.25+ -0.34 ℃; the Tm2 value is 82.12 +/-0.75 ℃; the Tonset value is 56.64 +/-0.00 ℃; the Tagg value is 81.13 +/-0.15 ℃;
the results for single domain antibody (2) are shown in FIG. 8; the Tm1 value thereof is 65.46 +/-0.27 ℃; the Tm2 value is 80.92+ -0.31 ℃; the Tonset value is 53.28 +/-0.61 ℃; the Tagg value is 79.86+/-0.00 ℃;
the results of the tandem nanobody are shown in figure 9. The Tm1 value thereof is 66.10 +/-0.02 ℃; the Tm2 value is 82.45+ -0.04 ℃; the TONSet value is 59.42+/-0.39 ℃; the Tagg value is 65.86+/-0.15 ℃;
the stability effect of the tandem nanobody is significantly better than that of the control antibody.
Application example 1 an antibody preparation
This example provides an antibody preparation comprising the tandem antibody prepared in example 1.
The auxiliary materials of the preparation comprise:
the buffer is selected from: acetic buffer, histidine buffer, phosphate buffer, citrate buffer, carbonate buffer or Tris; the concentration of the buffer is 3-60mM.
The stabilizer is selected from: arginine salts, sodium chloride, mannitol, sorbitol, sucrose, glycine, and trehalose; the concentration of the stabilizer is 50-400mM. The combination of sucrose and arginine hydrochloride is selected, wherein the concentration of sucrose is 50-200mM, and the concentration of arginine hydrochloride is 10-100mM.
The surfactant is selected from: polysorbate 80, polysorbate 20 and poloxamer 188.
Application example 2A kit
This example provides a kit for in vitro detection of IL-17A.
The kit is a competition ELISA kit and comprises a colloidal gold reagent strip and sample diluent.
The colloidal gold reagent strip comprises: sample pad, gold mark pad, chromatographic membrane and absorbent paper.
The gold-labeled pad is coated with the serial antibody prepared in the colloidal gold-labeled example 1;
a detection line and a quality control line are arranged on the chromatographic membrane, and the detection line is coated with an IL-17A antigen marked by colloidal gold; the quality control line is coated with the verification antibody of the tandem antibody.
When the sample is used, the sample dilution liquid is used for diluting the sample, the sample is dripped on a sample pad, when the sample contains a certain amount of IL-17A, the sample reacts with the colloidal gold labeled antibody, the detection line does not display color, and when the sample does not contain IL-17A, the colloidal gold labeled antibody reacts with the coating antigen on the detection limit, and the color is displayed, so that the detection purpose is achieved.
The kit can also be established by a double-antibody sandwich method, and the tandem antibody prepared in the embodiment 1 can be used as an enzyme-labeled antibody or a solid-phase antibody.
Application example 3 an antibody conjugate
This example provides antibody conjugates of tandem antibodies prepared in example 1.
The preparation method comprises the following steps:
(1) Reacting the tandem antibody or antigen-binding fragment thereof with a reducing agent in a buffer;
(2) Reacting the linker-payload with the thiol-bearing tandem antibody or antigen-binding fragment thereof obtained in step (1);
the mass ratio of reducing agent to tandem antibody or antigen binding fragment thereof is 1:1-5:1; preferably 1:1 to 4:1; further preferably 1:1 to 3:1; even more preferably 2:1 to 3:1.
The reducing agent is selected from tris (2-carboxyethyl) phosphine (TCEP) or a salt thereof, dithiothreitol or 2-mercaptoethanol. In some embodiments the reducing agent is tris (2-carboxyethyl) phosphine or a salt thereof, preferably tris (2-carboxyethyl) phosphine hydrochloride (tcep·hcl).
The buffer solution is selected from HEPES (4- (2-hydroxyethyl) -1-piperazine ethane sulfonic acid) buffer solution, histidine buffer solution, phosphate buffer solution, borate buffer solution or acetate buffer solution; preferably histidine buffer; further preferred is histidine-hydrochloric acid buffer; the concentration of the buffer is 1mM-30mM, such as 5mM, 10mM, 15mM, 20mM, 25mM or 30mM, preferably 20mM.
The ratio of the amount of the linker-payload to the amount of the substance of the tandem antibody or antigen binding fragment thereof is 2:1-10:1; preferably, the ratio of the amount of linker-payload to the amount of substance of the tandem antibody or antigen binding fragment thereof is 3:1-9:1; further preferred, the ratio of the amount of linker-payload to the amount of substance of the tandem antibody or antigen binding fragment thereof is 4:1-7:1; further preferably, the ratio of the amount of the linker-payload to the amount of the substance of the tandem antibody or antigen binding fragment thereof is from 5:1 to 7:1.
The solvent used to dissolve the linker-payload may be selected from aqueous acetone (e.g., 50% aqueous acetone), aqueous ethanol (e.g., 80% aqueous ethanol), aqueous methanol (e.g., 80% aqueous methanol), aqueous isopropanol (e.g., 80% aqueous isopropanol), aqueous dimethyl sulfoxide (e.g., 80% aqueous dimethyl sulfoxide), acetone, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), or N-methyl-2-pyrrolidone (NMP); preferably an aqueous acetone or DMSO, preferably 50% aqueous acetone.
Application example 4A pharmaceutical composition for the treatment of tumors
This example provides a pharmaceutical composition comprising the tandem antibodies prepared in the example.
The pharmaceutical composition also comprises any one or more of the following medicines:
nitrogen mustard, cyclophosphamide, ifosfamide, phenylalanine nitrogen mustard, chlorambucil, thiotepa, carmustine, lomustine, nimustine, busulfan, methotrexate, thioguanine, fluorouracil, capecitabine, deoxyfluorouridine, famoxadine, dactinomycin, mitomycin, bleomycin, pingyanmycin, doxorubicin, epirubicin, pyranamycin, mithramycin, mitoxantrone, vincristine, vindesine, vinorelbine, etoposide, teniposide, hydroxycamptothecin, topotecan, paclitaxel, dacarbazine, cisplatin, carboplatin, oxaliplatin, nedaplatin, erlotinib, cetuximab, bevacizumab, an Luoti, trastuzumab, palivizumab, katuzumab, imatinib, dulcitol You Shan, dittany Li Shan, gartuzumab, and nervogliboside Li Shan.
The pharmaceutical composition may be an antibody combination: for example, the serial antibody and palbociclib are used for treating cancer under the condition of a certain dosage ratio (such as 1:1).
The pharmaceutical composition may also be a combination of different types of drugs: such as tandem antibodies in combination with cisplatin for the treatment of cancer.
It should be noted that the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the scope of the present invention, and those skilled in the art should substitute and improve the simple means based on the technical solution provided by the present invention.

Claims (27)

1. An antibody, comprising:
(1) First single domain antibody:
the amino acid sequence comprises: HCDR1, HCDR2, HCDR3 as shown in SEQ ID nos. 1-3; and/or; an amino acid sequence having at least 80% sequence identity to the amino acid sequences shown in SEQ ID NO. 1-3;
SEQ ID NO.1：ESLLRLYA；
SEQ ID NO.2：HTTSDTT；
SEQ ID NO.3：HVTSMRDSQNY；
(2) Second single domain antibody:
the amino acid sequence comprises HCDR4, HCDR5 and HCDR6 shown in SEQ ID NO. 4-6; and/or; an amino acid sequence having at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO. 4-6;
SEQ ID NO.4：TIGLSIYS；
SEQ ID NO.5：ITRRGVT；
SEQ ID NO.6：NVGGEDGY。
2. the antibody of claim 1, wherein the amino acid sequence comprises: an amino acid sequence obtained by at least one of addition, deletion, modification and/or substitution on the amino acid sequence shown in SEQ ID NO. 1-6.
3. The antibody of claim 2, wherein the amino acid sequence of the antibody comprises: amino acid sequences having a difference of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids compared to the amino acid sequences shown in SEQ ID NO. 1-6.
4. The antibody of any one of claims 1-3, wherein the first single domain antibody or the second single domain antibody further comprises at least 4 FR regions for linking heavy chain variable regions.
5. The antibody of claim 4, wherein the heavy chain framework region comprises a portion or all of an antibody heavy chain framework region selected from human, murine, primate, or camelid sources or a variant thereof;
preferably, the antibody heavy chain framework regions or variants thereof comprise part or all of a source selected from camelids;
more preferably, the heavy chain framework regions of the antibodies or variants thereof are comprised in part or in whole selected from alpaca sources.
6. An antibody, comprising:
a first single domain antibody of the formula (i):
FR1-HCDR1-FR2-HCDR2-FR3-HCDR3-FR4；
(ii) a second single domain antibody, said second single domain antibody having the structure:
FR5-HCDR4-FR6-HCDR5-FR7-HCDR6-FR8；
wherein HCDR1, HCDR2 and HCDR3 are selected from the group consisting of:
amino acid sequences as shown in SEQ ID NO. 1-3; or; amino acid sequence having a 1, 2 or 3 amino acid difference compared to SEQ ID No. 1-3;
HCDR4, HCDR5 and HCDR6 are selected from:
amino acid sequence shown as SEQ ID NO. 4-6; or; amino acid sequence having a 1, 2 or 3 amino acid difference compared to SEQ ID No. 4-6;
FR1, FR2, FR3 and FR4 are selected from: amino acid sequence shown as SEQ ID NO. 7-10; or; an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity compared to SEQ ID No. 7-10;
FR5, FR6, FR7 and FR8 are selected from: amino acid sequences as shown in SEQ ID NO. 11-14; or; an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity compared to SEQ ID No. 11-14;
the amino acid sequence difference is realized by at least one mode of adding, deleting, modifying and/or substituting on the amino acid sequences shown in SEQ ID NO. 1-3.
7. The antibody of claim 6, wherein HCDR1 has an amino acid sequence shown as SEQ ID No.1, HCDR2 has an amino acid sequence shown as SEQ ID No.2, HCDR3 has an amino acid sequence shown as SEQ ID No.3, HCDR4 has an amino acid sequence shown as SEQ ID No.4, HCDR5 has an amino acid sequence shown as SEQ ID No.5, and HCDR6 has an amino acid sequence shown as SEQ ID No. 6.
8. The antibody of any one of claims 1-7, wherein the amino acid sequences of the first single domain antibody and the second single domain antibody are directly linked; or; indirectly connected through a linker.
9. The antibody of claim 8, wherein the linker is (GGGGS) n, wherein n is selected from 1, 2, 3, 4, 5 or 6; preferably, the linker is (GGGGS) 3 。
10. The antibody of any one of claims 1-9, wherein the first single domain antibody and the second single domain antibody are linked in an optional order; or; the first single domain antibody and the second single domain antibody are connected in the order from the N end to the C end; or; the first single domain antibody and the second single domain antibody are linked in order from the C-terminus to the N-terminus.
11. The antibody of any one of claims 1-10, which is an anti-IL-17A antibody.
12. A recombinant protein comprising the antibody of any one of claims 1-11.
13. The recombinant protein according to claim 12, wherein said recombinant protein further comprises a biologically active protein or functional fragment thereof that facilitates expression and/or secretion, or that increases in vivo half-life.
14. The recombinant protein according to claim 13, wherein said biologically active protein or functional fragment thereof is selected from at least one of an immunoglobulin Fc domain, serum albumin, albumin binding polypeptide, prealbumin, carboxy terminal peptide, elastin-like polypeptide, his tag, GST tag, MBP tag, FLAG tag, and SUMO tag.
15. The recombinant protein according to claim 14, wherein said immunoglobulin Fc domain is derived from a human antibody, a murine antibody, a primate antibody or a camelid antibody, or a variant thereof;
preferably, the immunoglobulin Fc domain is derived from a human IgG antibody, such as an IgG1 Fc, an IgG2 Fc, an IgG3 Fc or an IgG4 Fc, preferably an IgG1 Fc.
16. An antibody preparation, comprising:
a1: the antibody of any one of claims 1-11 or the recombinant protein of any one of claims 12-15; and
a2: a pharmaceutically acceptable carrier.
17. Kit, characterized in that it comprises an antibody according to any one of claims 1 to 11, a recombinant protein according to any one of claims 12 to 15 or an antibody preparation according to claim 16;
optionally, the kit further comprises a container for loading the antibody preparation.
18. A drug conjugate, comprising:
b1: the antibody of any one of claims 1-11 or the recombinant protein of any one of claims 12-15; and
b2: a coupling moiety coupled to B1.
19. An isolated nucleic acid molecule encoding the antibody of any one of claims 1-11 or the recombinant protein of any one of claims 12-15.
20. An expression vector comprising the nucleic acid molecule of claim 19.
21. A pharmaceutical composition comprising the antibody of any one of claims 1-11, the recombinant protein of any one of claims 12-15, the antibody preparation of claim 16, the drug conjugate of claim 18, the nucleic acid molecule of claim 19 or the expression vector of claim 20;
optionally, the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.
22. The antibody of any one of claims 1-11, the recombinant protein of any one of claims 12-15, the antibody preparation of claim 16, the drug conjugate of claim 18, or the pharmaceutical composition of claim 21 for at least one of the following uses:
c1: preparing a detection reagent or a kit;
c2: preparing a medicament for preventing and/or treating autoimmune diseases;
and C3: preparing medicine for preventing and/or treating cancer.
23. The use according to claim 22, characterized in that, the autoimmune disease includes Behcet's disease, systemic lupus erythematosus, chronic discoid lupus erythematosus, multiple sclerosis, systemic scleroderma, progressive systemic sclerosis, scleroderma, polymyositis, dermatomyositis, perinodular arteritis, aortitis syndrome, malignant rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, mixed connective tissue disease, kasmann's disease, sjogren's syndrome, adult Steve's disease, vasculitis, allergic granulomatous vasculitis, allergic vasculitis, rheumatoid vasculitis, macrovasculitis, ANCA-related vasculitis, cogan's syndrome, RS3PE syndrome, temporal arteritis, polymyositis rheumatica, fibromyalgia, antiphospholipid antibody syndrome, eosinophilic fasciitis, igG 4-related diseases, guillain Barre syndrome myasthenia gravis, chronic atrophic gastritis, autoimmune hepatitis, nonalcoholic steatohepatitis, primary biliary cirrhosis, good-pasture syndrome, acute glomerulonephritis, lupus nephritis, megaloblastic anemia, autoimmune hemolytic anemia, pernicious anemia, autoimmune neutropenia, idiopathic thrombocytopenic purpura, bazedol's disease, crohn's disease bridge disease, autoimmune adrenocortical insufficiency, primary hypothyroidism, addison's disease, idiopathic Addison's disease, type I diabetes, slowly progressive type I diabetes, focal scleroderma, psoriasis, psoriatic arthritis, bullous pemphigoid, herpes gestation, linear IgA bullous dermatoses, acquired epidermolysis bullosa, alopecia areata, leukoplakia, vitiligo vulgaris, neuromyelitis optica, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, sarcoidosis, giant cell arteritis, amyotrophic lateral sclerosis, former field disease, autoimmune optic neuropathy, idiopathic azoospermia, habitual abortion, inflammatory bowel disease, celiac disease, ankylosing spondylitis, severe asthma, chronic urticaria, familial mediterranean fever, eosinophilic chronic sinusitis, dilated cardiomyopathy, systemic mastocytosis or inclusion body myositis;
Preferably, the autoimmune disease is plaque psoriasis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or lupus nephritis.
24. The use according to claim 22 or 23, wherein the cancer comprises basal cell carcinoma, cholangiocarcinoma, bladder cancer, bone cancer, breast cancer, peritoneal cancer, cervical cancer, cholangiocarcinoma, choriocarcinoma, colorectal cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer, glioblastoma, liver cancer, renal cancer, laryngeal cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, respiratory cancer, salivary gland cancer, sarcoma, skin cancer, squamous cell carcinoma, testicular cancer, thyroid cancer, uterine cancer, urinary system cancer, B-cell lymphoma, chronic lymphoblastic leukemia, acute lymphoblastic leukemia, hairy cell leukemia or chronic myelogenous leukemia.
25. A method for in vitro detection of IL-17A in a sample for non-diagnostic purposes, characterized in that the method comprises the steps of:
D1: the antibody of any one of claims 1-11, the recombinant protein of any one of claims 12-15, the antibody preparation of claim 16, or the drug conjugate of claim 18, in contact with a sample to be tested;
d2: detecting the antigen-antibody complex;
d3: and judging the result.
26. A method of preventing and/or treating an autoimmune disease, the method comprising:
administering to a subject in need thereof a therapeutically effective amount of the antibody of any one of claims 1-11, the recombinant protein of any one of claims 12-15, the antibody preparation of claim 16, or the drug conjugate of claim 18.
27. A method of preventing and/or treating cancer, the method comprising:
administering to a subject in need thereof a therapeutically effective amount of the antibody of any one of claims 1-11, the recombinant protein of any one of claims 12-15, the antibody preparation of claim 16, or the drug conjugate of claim 18.
CN202311864200.7A 2023-12-29 2023-12-29 Novel antibodies and downstream products targeting interleukin family members Active CN117843801B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311864200.7A CN117843801B (en) 2023-12-29 2023-12-29 Novel antibodies and downstream products targeting interleukin family members

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311864200.7A CN117843801B (en) 2023-12-29 2023-12-29 Novel antibodies and downstream products targeting interleukin family members

Publications (2)

Publication Number Publication Date
CN117843801A true CN117843801A (en) 2024-04-09
CN117843801B CN117843801B (en) 2024-08-02

Family

ID=90541600

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311864200.7A Active CN117843801B (en) 2023-12-29 2023-12-29 Novel antibodies and downstream products targeting interleukin family members

Country Status (1)

Country Link
CN (1) CN117843801B (en)

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070118916A1 (en) * 2005-10-14 2007-05-24 Metanomics Gmbh Process for the production of fine chemicals
US20080241130A1 (en) * 2007-03-28 2008-10-02 Wright Jill F Methods and compositions for modulating il-17f/il-17a biological activity
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
CN101563098A (en) * 2006-11-29 2009-10-21 健泰科生物技术公司 IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20110182897A1 (en) * 2008-06-05 2011-07-28 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
CN102388069A (en) * 2009-04-10 2012-03-21 埃博灵克斯股份有限公司 Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
US20130121915A1 (en) * 2010-04-05 2013-05-16 Bar-Llan University Protease-activatable pore-forming polypeptides
CN103717618A (en) * 2011-05-05 2014-04-09 默克专利股份有限公司 Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
WO2014161570A1 (en) * 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US20170066843A1 (en) * 2014-09-26 2017-03-09 Closed Joint Stock Company "Biocad" High affinity and aggregatively stable antibodies on the basis of variable domains vl and a derivative vhh
CN110003329A (en) * 2019-04-12 2019-07-12 深圳普瑞金生物药业有限公司 Polypeptide, IL17A/F single domain antibody, nucleotide sequence and kit
CN110003337A (en) * 2019-04-12 2019-07-12 深圳普瑞金生物药业有限公司 IL17RA single domain antibody, nucleotide sequence and kit
CN112424224A (en) * 2018-05-30 2021-02-26 中山康方生物医药有限公司 anti-interleukin-17A antibodies, pharmaceutical compositions thereof, and uses thereof
US20210139566A1 (en) * 2012-05-31 2021-05-13 Government Of The United States As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against yersinia pestis and methods of use
CN113631574A (en) * 2019-01-31 2021-11-09 努玛治疗有限公司 Multispecific antibodies specific for TNF alpha and IL-17A, antibodies targeting IL-17A, and methods of use thereof
CN114286827A (en) * 2019-07-26 2022-04-05 神州细胞工程有限公司 Humanized anti-IL 17A antibodies and uses thereof
WO2023203549A1 (en) * 2022-04-22 2023-10-26 Moonlake Immunotherapeutics Ag Methods of achieving safe and sustained control of il-17-dependent conditions in subjects responsive to treatment with an anti-il 17a/f nanobody

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070118916A1 (en) * 2005-10-14 2007-05-24 Metanomics Gmbh Process for the production of fine chemicals
CN101563098A (en) * 2006-11-29 2009-10-21 健泰科生物技术公司 IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20080241130A1 (en) * 2007-03-28 2008-10-02 Wright Jill F Methods and compositions for modulating il-17f/il-17a biological activity
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
US20110182897A1 (en) * 2008-06-05 2011-07-28 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
CN102388069A (en) * 2009-04-10 2012-03-21 埃博灵克斯股份有限公司 Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
US20130121915A1 (en) * 2010-04-05 2013-05-16 Bar-Llan University Protease-activatable pore-forming polypeptides
CN103717618A (en) * 2011-05-05 2014-04-09 默克专利股份有限公司 Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
US20140314743A1 (en) * 2011-05-05 2014-10-23 Merck Patent Gmbh Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
US20210139566A1 (en) * 2012-05-31 2021-05-13 Government Of The United States As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against yersinia pestis and methods of use
WO2014161570A1 (en) * 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US20170066843A1 (en) * 2014-09-26 2017-03-09 Closed Joint Stock Company "Biocad" High affinity and aggregatively stable antibodies on the basis of variable domains vl and a derivative vhh
CN112424224A (en) * 2018-05-30 2021-02-26 中山康方生物医药有限公司 anti-interleukin-17A antibodies, pharmaceutical compositions thereof, and uses thereof
US20210122815A1 (en) * 2018-05-30 2021-04-29 Akeso Biopharma, Inc. Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof
CN113631574A (en) * 2019-01-31 2021-11-09 努玛治疗有限公司 Multispecific antibodies specific for TNF alpha and IL-17A, antibodies targeting IL-17A, and methods of use thereof
CN110003329A (en) * 2019-04-12 2019-07-12 深圳普瑞金生物药业有限公司 Polypeptide, IL17A/F single domain antibody, nucleotide sequence and kit
CN110003337A (en) * 2019-04-12 2019-07-12 深圳普瑞金生物药业有限公司 IL17RA single domain antibody, nucleotide sequence and kit
CN114286827A (en) * 2019-07-26 2022-04-05 神州细胞工程有限公司 Humanized anti-IL 17A antibodies and uses thereof
WO2023203549A1 (en) * 2022-04-22 2023-10-26 Moonlake Immunotherapeutics Ag Methods of achieving safe and sustained control of il-17-dependent conditions in subjects responsive to treatment with an anti-il 17a/f nanobody

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GENBANK: "6B20_E: Chain E, Nanobody against G protein beta gamma dimer", 《GENBANK》, 4 October 2023 (2023-10-04) *
GENBANK: "AHY24765.1: immunoglobulin heavy chain variable region, partial [Lama glama]", 《GENBANK》, 5 May 2014 (2014-05-05) *
OLGA KOSTAREVA等: "Two Epitope Regions Revealed in the Complex of IL-17A and Anti-IL-17A VHH Domain", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》, vol. 23, no. 23, 28 November 2022 (2022-11-28), pages 14904 *
YIQIU YAO等: "Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa", 《DRUGS OF THE FUTURE》, vol. 47, no. 08, 24 August 2022 (2022-08-24), pages 567 - 573 *
王国庆、刘燕、高鸿霞: "IL-17A在乳腺浸润性导管癌中表达及对MCF-7细胞增殖转移的作用", 《北华大学学报(自然科学版)》, vol. 19, no. 05, 10 September 2018 (2018-09-10), pages 618 - 618 *
董芳、沈佳庆: "白介素17A在小鼠急性胰腺炎中的表达研究", 《胃肠病学和肝病学杂志》, vol. 22, no. 11, 20 November 2013 (2013-11-20), pages 1076 - 1078 *
陈莹莹等: "IL-17A单克隆抗体生物学活性检测方法的建立", 《中国现代应用药学》, vol. 40, no. 06, 28 March 2023 (2023-03-28), pages 808 - 811 *

Also Published As

Publication number Publication date
CN117843801B (en) 2024-08-02

Similar Documents

Publication Publication Date Title
CN107849136B (en) anti-TfR antibodies and their use in the treatment of proliferative and inflammatory diseases
BR112020012464A2 (en) bispecific antigen binding molecule; recombinant fusion protein, chimeric antigen receptor, cell, nucleic acid sequence, vector, host cell, method for preparing a bispecific antigen binding molecule, recombinant fusion protein or chimeric antigen receptor, pharmaceutical composition, use of a molecule bispecific antigen binding method, method for treating a disease in a patient in need of treatment, method for assessing the presence of a target analyte in a sample, method for imaging a disease site in an individual, method for diagnosing a disease or medical condition in an individual, antibody, antibody fragment or antigen-binding molecule, kit and method for diagnosing an individual suffering from cancer, or a predisposition for it, or to provide a prognosis of the condition of a individual, method to eliminate or inhibit the growth of a cell that expresses ror1 and egfr in vitro or in a patient
KR20180103084A (en) BCMA and CD3 bispecific T cell engrafting antibody constructs
JP2012135311A (en) Bispecific domain antibody with increased serum half life
CN117820479A (en) Novel nanobody against IL-17A
CN117820478A (en) Tandem molecules of nanobodies and their use in the treatment of diseases
CN112409480B (en) Serum albumin binding proteins and uses thereof
CN110724194B (en) anti-HER 3 humanized monoclonal antibody and preparation thereof
CN117843803A (en) Novel tandem single domain antibodies and their use in the treatment of disease
US11859001B2 (en) IL12RB1-Binding molecules and methods of use
CA3164979A1 (en) New polypeptide complex
US11623963B2 (en) Cysteine engineered antigen-binding molecules
JP2023175822A (en) specific binding molecules
JP2022521956A (en) Antigen-binding protein that binds to BCMA
CA2983537A1 (en) Method for increasing the percentage of monomeric antibody fab-dsfv multimeric species
CN117820477A (en) Novel anti-IL-17A single domain antibody concatemer and application thereof
CN117866903B (en) Single domain antibody modified stem cells and their use in the treatment of disease
JP7076571B2 (en) Cell engagement binding molecule
CN117820480A (en) Nanometer antibody concatemer, coding gene and application
CN117860786A (en) Pharmaceutical and diagnostic use of genetically modified mesenchymal stem cells in a variety of diseases
CN117843777A (en) Novel nanobody for the treatment of inflammatory diseases, and products and methods thereof
CN115776898A (en) Bispecific antibodies and uses thereof
CN114340668A (en) Heterodimeric antibodies binding to CD38 and CD3
CN117843801B (en) Novel antibodies and downstream products targeting interleukin family members
CN118206654A (en) Novel antibodies for the treatment of diseases, products and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant